Harrow (HROW) Non Operating Income (2013 - 2025)
Harrow's (HROW) quarterly Non Operating Income came in at -$5.2 million in Q4 2025, up 21.73% year-on-year from -$4.3 million in Q4 2024, and up 62.16% quarter-over-quarter from -$13.7 million in Q3 2025.
Harrow (HROW) Non Operating Income (2013 - 2025) Analysis & Trends
Harrow's Non Operating Income history runs 13 years deep, the most recent figure standing at -$5.2 million for Q4 2025.
- On a quarterly basis, Non Operating Income rose 21.73% year-over-year to -$5.2 million in Q4 2025; TTM through Dec 2025 was -$31.9 million, a 21.96% decrease from a year earlier, with the FY2025 full-year figure at -$31.9 million, down 21.96% from the prior year.
- Non Operating Income advanced to -$5.2 million in Q4 2025 per HROW's latest filing, from -$13.7 million in the prior quarter.
- Across five years, Non Operating Income topped out at $2.8 million in Q4 2022 and bottomed at -$13.7 million in Q3 2025.
- The 5-year median for Non Operating Income is -$6.4 million (2022), against an average of -$5.9 million.
- Across the five-year window, Non Operating Income slumped 325.32% in 2021 and surged 151.23% in 2022, its largest moves.
- Year by year, Non Operating Income stood at -$5.5 million in 2021, then jumped by 151.23% to $2.8 million in 2022, then tumbled by 269.71% to -$4.8 million in 2023, then plunged by 38.02% to -$6.6 million in 2024, then gained by 21.73% to -$5.2 million in 2025.
- Per Business Quant, the three latest HROW Non Operating Income figures stand at -$5.2 million (Q4 2025), -$13.7 million (Q3 2025), and -$6.4 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.19 Mn |
| Sep 30, 2025 | -13.73 Mn |
| Jun 30, 2025 | -6.41 Mn |
| Mar 31, 2025 | -6.55 Mn |
| Dec 31, 2024 | -6.64 Mn |
| Sep 30, 2024 | -5.52 Mn |
| Jun 30, 2024 | -7.35 Mn |
| Mar 31, 2024 | -6.64 Mn |
| Dec 31, 2023 | -4.81 Mn |
| Sep 30, 2023 | -4.60 Mn |
| Jun 30, 2023 | -6.60 Mn |
| Mar 31, 2023 | -8.14 Mn |
| Dec 31, 2022 | 2.83 Mn |
| Sep 30, 2022 | -6.34 Mn |
| Jun 30, 2022 | -7.89 Mn |
| Mar 31, 2022 | -4.54 Mn |
| Dec 31, 2021 | -5.53 Mn |
| Sep 30, 2021 | -4.61 Mn |
| Jun 30, 2021 | -6.65 Mn |
| Mar 31, 2021 | -2.70 Mn |